

INSIGHTS IN ESSENTIAL MEDICINE AVAILABILITY AND ACCESSIBILITY FROM ESMO ANTINEOPLASTIC MEDICINES STUDY 2.0

Nathan Cherny, on behalf of the collaborating partners

Shaare Zedek Medical Center, Jerusalem, Israel



DECLARATION OF INTERESTS

Nathan Cherny

No conflicts to disclose







PROJECT RATIONALE



ESMO is committed to assuring timely and optimal treatment to cancer patients The availability of antineoplastics directly affects the daily practice of clinicians and their ability to treat cancer patients



Affordability of medications impacts the equitable distribution of cancer care





For more information : https://www.esmo.org/policy/accessibility-and-availability-of-medicines

COMMON ISSUES WITH ANTI-NEOPLASTIC AGENTS

LIMITATIONS IN FORMULARY

No comprehensive mapping of formularies

ACTUAL AVAILABILITY AND AFFORDIBILITY



BARRIERS OF ACCESSIBILITY


shortages distribution manufacturing

AIMS OF THE STUDY

To **update** data regarding availability of cancer medicines in Europe, and the "Rest of the World" Factors adversely Formulary Availability of Patient 'out-ofimpacting cancer availability of pocket' cost for medication for medicine licensed antithe medication patients with a availability neoplastic medicines valid prescription

STUDY DEVELOPMENT

Modelled on previous ESMO Consortium Study on the Availability of Anti-Neoplastic Medicines (ANMS)








Ref: Cherny, Ann Onc 2016 (Europe); Cherny, Ann Onc 2017 (Global); Chern, Ann Onc 2013 (Global Opioid Policy Initiative)

DISEASE AREAS SURVEYED





EXAMPLE OF SURVEY: METASTIC BREAST CANCER

| | Is this medicine available for this indication? | (wha | st of the n t proporti es the av | on of the | full retail | price | most | patients in | your co | dicine when neo untry (can the pa when it is pres | atient | If the medicine is not always available, what is the main reason for this? | | | | | | Has the availability of this medicine been impacted by COVID-19? | | |
|---|---|-----------|--|--------------------|---|--------------|--------|-------------|---------------------|---|------------|--|---------------------------------|----------------------------|------------------------------|------------------------------|-------------------|---|------------|--|
| | Yes No | Free | <25% cost | 25- 50% cost | >50% cost but less than full cost | Full cost | Always | Usually | Half the time | Occasionally | Never | No / unreliable supplier * (1) | No commerical motive *(2) | Parallel export *(3) | Manufacturing issues *(4) | Budget capitation *(5) | Do not know | Yes | No | |
| Albumin- bound paclitaxel | ОС | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Abemaciclib | ОC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Alpelisib | ОC | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | \bigcirc | 0 | 0 | 0 | 0 | 0 | |
| Anastrozole | | $ \circ $ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | \circ | 0 | 0 | 0 | 0 | 0 | 0 | |
| Atezolizumab | 0 C | $ \circ $ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Bevacizumab Bevacizumab (and its quality- assured biosimilars) | 0 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Eribulin | O C | 0 | \bigcirc | 0 | 0 | 0 | 0 | 0 | 0 | \bigcirc | \bigcirc | 0 | \bigcirc | 0 | 0 | 0 | 0 | 0 | 0 | |
| Everolimus | O C | 0 | 0 | 0 | 0 | 0 | 0 | \bigcirc | 0 | \bigcirc | \bigcirc | 0 | \circ | \bigcirc | \bigcirc | 0 | 0 | 0 | \bigcirc | |
| Examestane | 0 0 | 0 | 0 | 0 | 0 | Ο | 0 | 0 | 0 | \circ | 0 | 0 | \bigcirc | 0 | \circ | 0 | Ο | 0 | 0 | |
| Fulvestrant | 0 C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | \bigcirc | 0 | 0 | 0 | 0 | 0 | 0 | |



IDENTIFICATION OF DATA REPORTERS



PEER REVIEW

The peer review process is essential to support the robustness of the information provided, to indicate discrepancies in the data, and to provide additional information on the actual situation in the various countries.



The preliminary data were posted on the ESMO website for external validation in August 2023, for a month



Invitations were sent to all members of the collaborating partner organisations, to those who were invited to complete the survey (both those who completed and those who didn't) and was open to all ESMO members to review the data and submit any correction or amendment




Amendments were collated, crosschecked, and incorporated into the final results



PEER REVIEW - RESULTS

269 experts from 107 countries completed the peer review – **17 new countries**





DATA COLLECTION AND MANAGEMENT

Electronic dissemination of survey and automated data entry

Crosschecking data entry and identification of discrepancies between reporters


Representative data presented

Preliminary report at #ESMO 2022

Collection of missing reports and open peer review of collated data

Final data report #ESMO 2023

COLOUR-CODED, TABULATED DATA PRESENTATION



Methodology similar to that developed by ESMO for studies on the availability of opioids for cancer pain management and antineoplastic agents Tables with colour-coded, tabulated data

Readily allows crosscounty comparisons

Data presentation facilitates tracking changes in availability over time



"WHO MODEL LIST OF ESSENTIAL MEDICINES"

Often referred to as the Essential Medicines List (EML)



Compilation of medications that WHO deems necessary for a basic healthcare system to function effectively



- These medicines are considered essential because
 - 1. they address the most important healthcare needs
 - 2. considered cost-effective, safe, and readily available



EML is updated regularly to reflect current medical knowledge and changing health priorities



WHO EML HISTORY




- for primary healthcare
- List did not comprehensively cover cancer treatment options

1977-2023

- Over the years **more cancer** medicines
- Initially chemotherapy agents ٠
- Growing recognition of the ٠ importance of targeted therapies



ANTI-CANCER MEDICINES IN THE WHO EML



EML=Model List of Essential Medicines. EMLc=Model List of Essential Medicines for Children. UICC=Union for International Cancer Control.



Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, et al. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022;10(12):e1860-e6.

ANTI-CANCER MEDICINES FOR ADULT SOLID TUMORS ON THE WHO EML

| kics (X |
|--------------|
| gemcitabine |
| fosfamide |
| rinotecan |
| eucovorin |
| nethotrexate |
| oxaliplatin |
| oaclitaxel |
| vinblastine |
| vincristine |
| vinorelbine |
| vinorelbine |
| |
| |



abiraterone

anastrozole

bicalutamide

enzalutamide

flutamide

goserelin

tamoxifen

BIOLOGICAL nivolumab pembrolizumab afatinib erlotinib everolimus gefitinib imatinib trastuzumab



USES OF THE WHO EML



National formularies

- Many nations incorporate the WHO EML into their national drug policies and procurement processes
- Helps governments to prioritise for medicines availability and affordability within their healthcare systems



NGOs and donors

Can identify priorities in efforts to provide healthcare assistance and support to countries in need

The EML is a valuable tool for promoting access to essential medicines and improving healthcare outcomes globally



RESULTS 2023



AVAILABILITY AND ACCESSIBILITY OF CANCER MEDICINES

2023 update




252 experts from 110 countries



Peer review with 269 experts from 106 countries

Total of countries surveyed 127



COST AND AVAILABILITY OF MULTI-USE ESSENTIAL MEDICINES

High-income

| Country | CarboPl | CisPl | OxaliPl | Dox | 5FU | Capecit | Gemcit | Irino | PacliTx | DoceTx |
|----------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Australia | Free | Free | Free | Free | Free | <25% cost | Free | Free | Free | Free |
| Austria | Free |
| Belgium | Free |
| Canada | Free |
| Chile | <25% cost |
| Taiwan | Free |
| Croatia | Free |
| Cyprus | Free |
| Czech Republic | Free |
| Denmark | Free |
| Estonia | Free |
| Finland | Free | Free | Free | Free | Free | <25% cost | Free | Free | Free | Free |
| France | Free |
| Germany | Free |
| Greece | Free |
| Hungary | Free |
| Iceland | Free |
| Ireland | Free |
| Israel | Free |
| Italy | Free |
| Japan | <25% cost |
| Korea | <25% cost |
| Kuwait | Free |
| Latvia | Free |
| Lithuania | Free |
| Luxembourg | Free |
| Malta | Free |
| Netherlands | Free |
| New Zealand | Free | Free | Free | Free | Free | <25% cost | Free | Free | Free | Free |
| Norway | Free |
| Oman | Free |
| Poland | Free |
| Portugal | Free |
| Qatar | Free |
| Saudi Arabia | Free |
| Singapore | Free |
| Slovakia | Free |
| Slovenia | Free |
| Spain | Free |
| Sweden | Free |
| Switzerland | Free |
| UAE | Free |
| United Kingdom | Free |
| USA | <25% cost |

Upper-middle income

| Country | CarboPl | CisPl | OxaliPl | Dox | 5FU | Capecit | Gemcit | Irino | PacliTx | DoceTx |
|-----------------|---------------------------------|---------------------------------|---------------------------------|-----------|-----------|---------------------------------|---------------------------------|----------------------------|---------------------------------|---------------------------------|
| Albania | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Argentina | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Armenia | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | Free | Free | >50% but less than full cost | >50% but less than full cost | >50% but less than full | >50% but less than full cost | >50% but less than full cost |
| Azerbaijan | Free | Free | Free | Free | Free | | Free | Free | Free | Free |
| Belarus | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Bosnia + HGV | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Botswana | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Brazil | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Bulgaria | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| China | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Colombia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Costa Rica | <25% cost | <25% cost | <25% cost | Free | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Cuba | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Ecuador | | | | | | | | | | |
| Georgia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Guatemala | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Iraq | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Jamaica | Free | Free | Free | Free | Free | Free | Free | | Free | >50% but less than full cost |
| Kazakhstan | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Libya | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Malaysia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Mexico | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Moldova | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Montenegro | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Namibia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| North Macedonia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Peru | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Romania | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Russia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Serbia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| South Africa | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Suriname | <25% cost | Free | 25-50% cost | Free | Free | Free | 25-50% cost | | 25-50% cost | 25-50% cost |
| Thailand | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Türkiye | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Turkmenistan | Full cost | Free | | Free | Free | Free | >50% but less than full cost | | Full cost | 25-50% cost |

| Free | |
|------------------------------|--|
| <25% cost | |
| 25-50% cost | |
| >50% but less than full cost | |
| Full cost | |
| Not available | |

Low- and Lower-middle income

| Country | CarboPI | CisPl | OxaliPI | Dox | 5FU | Capecit | Gemcit | Irino | PacliTx | DoceTx |
|-----------------------------|---------------------------------|---------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-------------------------------|
| Algeria | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Bangladesh | Full cost | Full cost | | Full cost | | Full cost | | | Full cost | Full cost |
| Bolivia | >50% but less then full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less then full cost | >50% but less than full cost | >50% but les than full cos |
| Cambodia | Full cost | | | | | | | | | |
| Cameroon | Full cost | | | | | | | | | Full cost |
| Egypt | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| El Salvador | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Ghana | Full cost | | | | 25-50% cost | <25% cost | | | 25-50% cost | 25-50% cost |
| Haiti | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Honduras | Full cost | | | Full cost | Full cost | | | | Full cost | Full cost |
| India | Full cost | | | Full cost | Full cost | | | | Full cost | |
| Indonesia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Iran | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Kenya | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost |
| Lebanon | >50% but less then full cost | Full cost | >50% but less three full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | >50% but les |
| Mongolia | Free Free | Free | Free Free | Free | Free | Free | Free | Free | Free | Free Free |
| Morocco | 25-50% cost | 25-50% cost | <25% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | <25% cost | 25-50% cost |
| Mvanmar | 25-50% cost | Free | >50% but less | <25% cost | Free | Full cost | >50% but less | >50% but less | >50% but less | Full cost |
| Nepal | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Nicaragua | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Nigeria | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Pakistan | <25% cost | <25% cost | 25-50% cost | 25-50% cost | <25% cost | <25% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost |
| Palestine | Free | Free | Free | Free | Free | Free | Free | Free | Free | Eree |
| Papua New Guinea | >50% but less | >50% but less | Full cost | >50% but less | >50% but less | Full cost | Full cost | Full cost | Full cost | Full cost |
| Philippines | than full cost | than full cost | Full cost | than full cost | than full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Sri Lanka | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Tunisia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Tanzania | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Uzbekistan | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Vanuatu | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | | <25% cost | <25% cost |
| Vietnam | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Zambia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Zimbabwe | Free Full cost | Full cost | Free Full cost | Full cost | Full cost | Full cost | Free Full cost | Full cost | Full cost | Full cost |
| Afghanistan | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Argnanistan Burkina Faso | Full cost | Full cost | Full cost | Full cost | Full cost | TUT COS | Full cost | Full cost | Full cost | Full cost |
| Ethiopia | >50% but less | >50% but less | >50% but less | >50% but less | >50% but less | >50% but less | >50% but less | >50% but less | 350% but less | >50% but les |
| Liberia | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost <25% cost | than full cost |
| | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Madagascar Malawi | Full cost | Full cost | Full cost | Full cost Free | Full cost Free | Full cost Free | Full cost | Full cost Free | Full cost Free | Full cost |
| Malawi Niger | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost | Free Full cost |
| Niger Rwanda | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | |
| | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but less | Full cost >50% but les |
| Somalia | than full cost | than full cost | than full cost | than full cost | than full cost | than full cost | than full cost | than full cost | than full cost | than full cos |
| Sudan | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Syria | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Uganda | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Yemen | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Venezuela | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |

ACCESSIBILITY OF MULTI-USE ESSENTIAL MEDICINES

High-income

ountry CarboPI CisPI OxaliPI Dox 5FU Capeci Gemcit Irino PacliTx DoceT Australia Always Austria Always Always Always Aways Always Always Belgium Always Always Always Always Always Always Always Canada Always Always Always Chile Always Always Always Always Always Always Always Taiwan Always Always Alway Always Always Always Always Always Croatia Aways Always Always Always Always Always Aways Always Alway: Cyprus Always Always Always Always. Always Always Always Always Czech Republic Always Always Always Always Always Always Denmark Usually Usually Always Usually Usually Estonia Aways Always Always Always Always Always Always Always Always Always Finland kuali I kually (Kually Usually France Always Alway: Always Always Always Always Always Always Always Germany Always Always Always Always Always Always Always Always Greece Aways Alway: Always Always Always Always Always Always Always Hungary Always Always Always Always Always Always Always Always Iceland Always Always Always Always Always Always Always Always Alway: Always Ireland Always Alway Always Alware Always Always Always Always Israel Aways Always Aluctor Always Always Aways Always Always Always Italy Always Always Always Alware Always Always Alwaye Always Always Japan Always Always Alway: Always Always Always Always Korea Always Always Always Always Always Always Always Always Kuwait Always Always Always Always Always Always Always Always Always Latvia Usually Usually Usuali Usually Usually Usualli Always Always l ithuania Always Luxembourg Always Always Always Always Always Always Always Always Malta Always Always Alway: Always Always Alwaya Always Always Netherlands Always Always Always Always Always Always Always Always New Zealand Always Always Always Always Always Always Always Always Norway Always Always Always Always Always Oman Always Always Usuali Always Always Usually Usually Poland Always Always Always Always Always Always Always Always Alway: Portuga Always Alway: Always Always Always Aways Always Always Always Qatar Always Δίωσυ Always Always Always Always Always Always Always Saudi Arabia Always Always Always Always Always Always Singapore Always Always Always Always Always Always Always Slovakia Always Always Always Always Always Always Always Always Slovenia Always Always Always Always Always Always Alway: Always Spain Always Always Always Always Always Always Always Sweden Always Always Always Always Always Alway Always Always Always Switzerland Always Always Always Always Always Always Always Always UAE Always Always Always Always Aways Always Always Always United Kingdom Always Always Always. Always Always Always Always Abacava Always USA Always Always Awars Always

Upper-middle income

Low + Lower-middle income


| Country | CarboPI | CisPl | OxaliPl | Dox | 5FU | Capecit | Gemcit | Irino | PacliTx | DoceTy |
|-----------------|--------------|---------------|---------------|----------|----------|---------------|---------------|---------------|---------------|--------------|
| Albania | Always | Always | Always | Always | Always | Always | Always | Usually | Always | Always |
| Argentina | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Armenia | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Azerbaijan | Always | Always | Always | Always | Always | Usually | Always | Always | Always | Always |
| Belarus | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Bosnia + HGV | Always | Always | Always | Always | Usually | Usually | Always | Always | Always | Always |
| Botswana | Usually | Always | Usually | Always | Always | Usually | Usually | Usually | Always | Usually |
| Brazil | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Bulgaria | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| China | Always | Always | Always | Usually | Always | Always | Always | Always | Always | Always |
| Colombia | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| Costa Rica | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Cuba | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| Ecuador | | | | | | | | | | |
| Georgia | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Guatemala | Usually | Usually | Always | Always | Always | Always | Usually | Usually | Always | Always |
| Iraq | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| Jamaica | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Half the time | Usually | Usually |
| Kazakhstan | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Libya | Usually | Usually | Half the time | Half the | Half the | Usually | Half the time | Half the time | Half the time | Half the tir |
| Malaysia | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Mexico | Usually | Half the time | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| Moldova | Always | Always | Usually | Usually | Always | Always | Usually | Half the time | Usually | Usually |
| Montenegro | Usually | Always | Usually | Always | Usually | Always | Always | Usually | Usually | Usually |
| Namibia | Always | Always | Usually | Always | Always | Always | Always | Always | Always | Always |
| North Macedonia | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Peru | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Romania | Usually | Usually | Always | Usually | Usually | Usually | Usually | Always | Always | Usually |
| Russia | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Serbia | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| South Africa | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually | Usually |
| Suriname | Usually | Usually | Usually | Usually | Always | Usually | Half the time | | Usually | Half the tir |
| Thailand | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Türkiye | Always | Always | Always | Always | Always | Always | Always | Always | Always | Always |
| Turkmenistan | Occasionally | Half the time | | Usually | Usually | Half the time | Occasionally | | Half the time | Occasiona |

| Always | |
|---------------|--|
| Usually | |
| Half the time | |
| Occasionally | |
| Never | |
| Not available | |

| Country | CarboPI | CisPl | OxaliPl | Dox | 5FU | Capecit | Gemcit | Irino | PacliTx | DoceTx |
|------------------|---------------------------------|---------------------------------|---------------------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Algeria | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Bangladesh | Full cost | | | | | | | | | Full cost |
| Bolivia | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than | >50% but less than full cost |
| Cambodia | Full cost | | Full cost | | | | | | Full cost | Full cost |
| Cameroon | Full cost | | Full cost | | | Full cost | | | Full cost | Full cost |
| Egypt | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| El Salvador | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Ghana | Full cost | | | | 25-50% cost | <25% cost | | Full cost | 25-50% cost | 25-50% cost |
| Haiti | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Honduras | Full cost | | | | | | | | | Full cost |
| India | Full cost | | Full cost | | | Full cost | | Full cost | Full cost | Full cost |
| Indonesia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Iran | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Kenya | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost |
| Lebanon | >50% but less than full cost | | >50% but less than full cost | | | | | | Full cost | >50% but less than full cost |
| Mongolia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Morocco | 25-50% cost | 25-50% cost | <25% cost | 25-50% | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost | <25% cost | 25-50% cost |
| Myanmar | 25-50% cost | Free | >50% but less than full cort | <25% cost | Free | Full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than full cort | Full cost |
| Nepal | Full cost | | | | | | | | Full cost | Full cost |
| Nicaragua | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Nigeria | Full cost | | Full cost | | | Full cost | | Full cost | Full cost | Full cost |
| Pakistan | <25% cost | <25% cost | 25-50% cost | 25-50% | <25% cost | <25% cost | 25-50% cost | 25-50% cost | 25-50% cost | 25-50% cost |
| Palestine | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Papua New Guinea | >50% but less than full cost | >50% but less than full cort | Full cost | >50% but | >50% but less than full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Philippines | Full cost | | Full cost | | | Full cost | | Full cost | Full cost | Full cost |
| Sri Lanka | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Tunisia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Tanzania | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Uzbekistan | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Vanuatu | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | | <25% cost | <25% cost |
| Vietnam | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Zambia | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Zimbabwe | Full cost | | Full cost | | | Full cost | | | | Full cost |
| Afghanistan | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Burkina Faso | Full cost | Full cost | Full cost | Full cost | | | | Full cost | Full cost | Full cost |
| Ethiopia | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than | >50% but less than full cost |
| Liberia | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Madagascar | Full cost | | | | | | | | | Full cost |
| Malawi | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Niger | Full cost | | | | | | | | | Full cost |
| Rwanda | Full cost | | Full cost | | | | | Full cost | Full cost | Full cost |
| Somalia | >50% but less than full cost | >50% but less than full cost | >50% but less than full cost | >50% but less than | >50% but less than full cost |
| Sudan | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Syria | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Uganda | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| Yemen | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |
| | | | | | | | | | | |
| Venezuela | Free | Free | Free | Free | Free | Free | Free | Free | Free | Free |

ESSENTIAL MEDICINES BIOLOGICAL THERAPIES

With high ESMO-MCBS scores (4-5 non-curative setting and A –B curative setting)





COST and AVAILABILITY

fatani

Free

25% cost

:25% cost

Free

Free Free

Free

Free

Free

Free

:25% cost

High-income

| | BREAST | | MELA | NOMA | | | LUNG | |
|----------------|--------------------|---|---------------|---------------|---|-----------|----------------|----|
| Country | Trastuzumab +BS | | Nivo | Pembro | | Erlotinib | Gefitinib | A |
| Australia | Free | | Free | Free | 1 | <25% cost | <25% cost | < |
| Austria | Free | | Free | Free | | Free | Free | |
| Belgium | Free | | Free | Free | | Free | Free | |
| Canada | Free | | Free | Free | | Free | Free | |
| Chile | Free | | Free | Free | | Free | Free | |
| Taiwan | Free | | Free | Free | | Free | Free | |
| Croatia | Free | | Free | Free | | Free | Free | |
| Cyprus | Free | | Free | Free | | Free | Free | |
| Czech Republic | Free | | Free | Free | | Free | Free | |
| Denmark | Free | | Free | Free | | Free | Free | |
| Estonia | Free | | | | | Free | Free | |
| Finland | Free | | Free | Free | | <25% cost | <25% cost | |
| France | Free | | Free | Free | | Free | Free | |
| Germany | Free | 1 | Free | Free | 1 | Free | Free | |
| Greece | Free | | Free | Free | | Free | Free | |
| Hungary | Free | | Free | Free | | Free | Free | |
| Iceland | Free | | Free | Free | | Free | Free | |
| Ireland | Free | 1 | Free | Free | 1 | Free | Free | |
| Israel | Free | 1 | Free | Free | 1 | Free | Free | |
| Italy | Free | 1 | Free | Free | 1 | Free | Free | |
| Japan | <25% cost | 1 | <25% cost | <25% cost | 1 | <25% cost | <25% cost | < |
| Korea | <25% cost | | <25% cost | <25% cost | 1 | <25% cost | <25% cost | ~ |
| Kuwait | Free | 1 | Free | Free | 1 | Free | Free | |
| Latvia | Free | 1 | Free | Free | 1 | Free | Free | |
| Lithuania | Free | 1 | Free | Free | 1 | Free | Free | |
| Luxembourg | Free | | Free | Free | | Free | Free | |
| Malta | Free | | Free | Full cost | | Free | | |
| Netherlands | Free | 1 | Free | Free | 1 | Free | Free | |
| New Zealand | Free | 1 | Free | Free | 1 | <25% cost | <25% cost | |
| Norway | Free | 1 | Free | Free | 1 | Free | Free | |
| Oman | Free | | Free | Free | | Free | Free | |
| Poland | Free | | Free | Free | l | Free | Free | |
| Portugal | Free | 1 | Free | Free | 1 | Free | Free | |
| Qatar | Free | | Free | Free | | Free | Free | |
| Saudi Arabia | Free | | Free | Free | | Free | Free | |
| Singapore | Free | | >50% cost but | >50% cost but | | Free | Free | 25 |
| Slovakia | Free | 1 | Full cost | Free | 1 | Free | Free | |
| Slovenia | Free | 1 | Free | Free | 1 | Free | Free | |
| Spain | Free | 1 | Free | Free | 1 | Free | Free | |
| Sweden | Free | 1 | Free | Free | 1 | Free | Free | |
| Switzerland | Free | 1 | Free | Free | 1 | Free | Free | |
| UAE | Free | | Free | Free | | Free | Free | |
| United Kingdom | Free | | Free | Free | | Free | Free | |
| USA | <25% cost | | <25% cost | <25% cost | | <25% cost | <25% cost | |
| | | 1 | | | 1 | | and the second | |

Upper-middle income

| | BREAST | MELA | NOMA | | LUNG | |
|-----------------|--------------------|-----------|-----------|-----------|-------------|-------------|
| Country | Trastuzumab +BS | Nivo | Pembro | Erlotinib | Gefitinib | Afatanib |
| Albania | Free | Full cost | Free | Free | | Full cost |
| Argentina | Free | Free | Free | Free | Free | Free |
| Armenia | Full cost | Full cost | Full cost | Full cost | | |
| Azerbaijan | Full cost | Full cost | Full cost | Full cost | | |
| Belarus | Free | Free | | Free | | |
| Bosnia + HGV | Free | Free | Free | Free | | |
| Botswana | Free | | Free | | | |
| Brazil | Free | Free | Free | Free | Free | Free |
| Bulgaria | Free | Free | Free | Free | Free | Free |
| China | <25% cost | Full cost | <25% cost | <25% cost | <25% cost | <25% cost |
| Colombia | Free | Free | Free | Free | Free | Free |
| Costa Rica | Free | | <25% cost | Free | 25-50% Cost | 25-50% Cost |
| Cuba | Free | | | | | |
| Ecuador | Free | | Free | | | Free |
| Georgia | <25% cost | Full cost | Full cost | Free | | Full cost |
| Guatemala | Full cost | | | | | |
| Iraq | Free | Free | Free | Free | Free | |
| Jamaica | Free | Full cost | Full cost | Full cost | | |
| Kazakhstan | Free | Full cost | Free | Free | Free | Free |
| Libya | Full cost | Full cost | Full cost | Full cost | | |
| Malaysia | <25% cost | Full cost | Full cost | Full cost | | <25% cost |
| Mexico | Free | Free | Free | Free | Free | Free |
| Moldova | | | | | | |
| Montenegro | Free | | Free | Free | Free | |
| Namibia | <25% cost | | | | | |
| North Macedonia | Free | Full cost | Free | Free | Free | Full cost |
| Peru | Free | Full cost | Full cost | Free | Full cost | |
| Romania | Free | Free | Free | Free | Free | Free |
| Russia | Free | Free | Free | Free | Free | Free |
| Serbia | Free | Free | Free | Free | Free | Free |
| South Africa | <25% cost | Full cost | Full cost | Full cost | Full cost | Full cost |
| Suriname | Full cost | | | | | |
| Thailand | <25% cost | Full cost | Full cost | Free | Free | Full cost |
| Türkiye | Free | Free | | Free | Free | Free |
| Turkmenistan | Free | Full cost | Full cost | Full cost | Full cost | Full cost |

| Free | |
|------------------------------|--|
| <25% cost | |
| 25-50% cost | |
| >50% but less than full cost | |
| Full cost | |
| Not available | |

Low + Lower-middle income

Algeria Banglades

Bolivia Cambodia

Egypt

Haiti

India Indonesia

Iran Kenya Lebanon

Cameroon

El Salvado Ghana

Honduras

Mongolia

Morocco

Myanmar Nepal

Nicaragua

Nigeria Pakistan

Palestine

Papua Nev

Philippines

Sri Lanka

Tanzania Uzbekistar

Vanuatu Vietnam

Zambia

Zimbabwe

Afghanista Burkina Fa

Ethiopia

Liberia Madagasca Malawi

Niger Rwanda

Somalia

Uganda

Yemen

Venezuela

Sudan Syria

Tunisia

| | BREAST | MELA | NOMA | | LUNG | |
|------------|--------------------------------------|----------------------------|----------------------------|----------------|------------------------|-----|
| | Trastuzumab | | Pembro | Erlotinib | O distantin | Afa |
| | +BS | Nivo | Pembro | Eriotinib | Gefitinib | AIG |
| | Free | | | Free | Free | |
| h | Full cost | Full cost | | Full cost | | |
| | Full cost | | | Full cost | | |
| | Full cost | Full cost | Full cost | Full cost | Full cost | F |
| | Full cost | Full cost | Full cost | | | |
| | Free | Full cost | Full cost | 25-50% cost | 25-50% cost | F |
| r | Free | | | Free | Free | |
| | Free | | | Full cost | | |
| | Full cost | | | | | |
| | Full cost | | Full cost | | | |
| | Full cost | Full cost | Full cost | Full cost | Full cost | F |
| | Free | Full cost | Full cost | Free | Free | |
| | <25% cost | Full cost >50% cost but | Full cost >50% cost but | <25% cost | Full cost | |
| | 25-50% cost | less than full | less than full | 25-50% cost | 25-50% cost | 25- |
| | <25% cost Free | | | | | |
| | Free | | -250/ | -25% | Full cost <25% cost | |
| | | | <25% cost | <25% cost | <25% COSt | |
| | Full cost | Full cost | Full cost | Full cost | Full cost | F |
| | Free | Full cost | Full cost | Full cost | Full cost | |
| | Full cost | T GH COAC | | Full cost | Tuncost | |
| | >50% cost but less than | | | >50% but less | >50% but less | |
| | full cost | Full cost | Full cost | than full cost | than full cost | F |
| | Free | Free | Free | Free | Free | |
| v Guinea | Full cost >50% cost but less than | | >50% cost but | Full cost | Full cost | |
| s | full cost | | less than full | Full cost | Full cost | F |
| | Free | | | | | |
| | | | | Free | | |
| | Free | Full cost | Full cost | | Full cost | |
| ו (| Free | Full cost | Full cost | | | |
| | 25-50% cost 25-50% cost | Full cost | Full cost | 25-50% cost | 25-50% cost | 25- |
| | 25-50% COSt | Full COSt | Full COSt | 20-50% COSt | 20-00% C0St | 25- |
| • | Full cost | Full cost | Full cost | Full cost | | |
| ın | Full cost | Full Cost | PullCost | Puil Cost | | |
| iso | Full cost | Full cost | Full cost | Full cost | Full cost | E |
| | | | | | | |
| | | | | | | |
| ar | Full cost | Full cost | Full cost | Full cost | Full cost | F |
| | Free | | | | | |
| | | | | | | |
| | Full cost | Full cost | Full cost | Full cost | | |
| | | | | | | |
| | Free | | | | | |
| | | | | | | |
| | | | | Free | | |
| | Free | 25-50% cost | Full cost | Free | Free | F |
| | Full cost | Full cost | Full cost | Full cost | Full cost | F |
| | | | | | | |

ACCESSIBILITY

High-income

fatanil

Always

Always

Always

Always

Always

Always

Al ways Al ways

Always

Usually

Always

Always

Always

casionall

f the tim

Always

casionall

casionall

Always

Always

Always

Always

Always

Always

Always

Always

Usually

| | BREAST | | MELA | NOMA | | | LUNG | |
|----------------|--------------------|---|---------------|---------|---|-----------|--------------|----|
| Country | Trastuzumab +BS | | Nivo | Pembro | | Erlotinib | Gefitinib | A |
| Australia | Always | | Always | Always | | Always | Always | |
| Austria | Always | | Always | Always | 1 | Always | Always | |
| Belgium | Always | 1 | Always | Always | 1 | Always | Always | |
| Canada | Always | | Always | Always | | Always | Always | |
| Chile | Always | | Usually | Usually | 1 | Always | Always | |
| Taiwan | Always | | Always | Always | | Always | Always | |
| Croatia | Always | | Always | Always | 1 | Always | Always | |
| Cyprus | Always | | Half the time | Always | 1 | Always | Always | на |
| Czech Republic | Always | | Always | Always | 1 | Always | Always | |
| Denmark | Usually | | Always | Always | 1 | Always | Always | |
| Estonia | Always | | Always | Always | 1 | Always | Always | |
| Finland | Always | 1 | Always | Always | 1 | Usually | Usually | |
| France | Always | 1 | Always | Always | 1 | Always | Always | |
| Germany | Always | | Always | Always | 1 | Always | Always | |
| Greece | Always | | Always | Always | 1 | Always | Always | |
| Hungary | Always | | Always | Always | 1 | Always | Always | 00 |
| Iceland | Always | | Always | Always | 1 | Always | Usually | |
| Ireland | Always | | Always | Always | 1 | Always | Usually | на |
| Israel | Always | | Always | Always | 1 | Always | Always | |
| Italy | Always | | Always | Always | 1 | Always | Always | |
| Japan | Always | | Always | Always | 1 | Always | Always | |
| Korea | Always | | Always | Always | 1 | Always | Always | |
| Kuwait | Always | | Always | Always | 1 | Always | Always | |
| Latvia | Always | | Usually | Usually | | Usually | Usually | |
| Lithuania | Always | | Always | Always | | Always | Always | |
| Luxembourg | Always | | Always | Always | 1 | Always | Always | |
| Malta | Always | | Always | Usually | 1 | Always | | |
| Netherlands | Always | | Always | Always | 1 | Always | Always | |
| New Zealand | Always | | Always | Always | | Always | Always | |
| Norway | Always | | Always | Always | 1 | Always | Always | |
| Oman | Always | | Always | Always | 1 | Always | Always | |
| Poland | Always | | Always | Always | 1 | Always | Always | |
| Portugal | Always | | Always | Always | 1 | Always | Always | |
| Qatar | Always | | Always | Always | 1 | Always | Occasionally | 00 |
| Saudi Arabia | Always | | Always | Always | 1 | Always | Usually | 00 |
| Singapore | Always | | Always | Always | | Always | Always | |
| Slovakia | Always | | Always | Always | | Always | Always | |
| Slovenia | Always | | Always | Always | | Always | Always | |
| Spain | Always | | Always | Always | 1 | Always | Always | |
| Sweden | Always | | Always | Always | 1 | Always | Always | |
| Switzerland | Always | | Always | Always | | Always | Always | |
| UAE | Always | | Always | Always | | Always | Always | |
| United Kingdom | Always | | Always | Always | 1 | Always | Always | |
| USA | Always | | Usually | Usually | | Always | Always | |
| USA | Andrays | | osualiy | osuany | | ruways | ra wa ys | |

Upper-middle income

| | BREAST | MELA | NOMA | LUNG | | |
|-----------------|--------------------|---------------|---------------|---------------|---------------|--------------|
| Country | Trastuzumab +BS | Nivo | Pembro | Erlotinib | Gefitinib | Afatanib |
| Albania | Always | | Half the time | Always | Never | Never |
| Argentina | Always | Always | Always | Always | Always | Usually |
| Armenia | Always | Always | Always | Always | Always | Usually |
| Azerbaijan | Always | Half the time | Half the time | Usually | Half the time | Occasionally |
| Belarus | Usually | Occasionally | | Occasionally | | |
| Bosnia + HGV | Usually | Usually | Usually | Always | | Never |
| Botswana | Always | | Usually | | | |
| Brazil | Always | Always | Always | Always | Always | Always |
| Bulgaria | Always | Always | Always | Always | Always | Always |
| China | Always | Always | Always | Always | Always | Always |
| Colombia | Always | Usually | Usually | Always | Always | Usually |
| Costa Rica | Usually | Never | Always | Occasionally | Occasionally | Never |
| Cuba | | | | | | |
| Ecuador | Usually | | Usually | | | Usually |
| Georgia | Always | Always | Always | Always | Never | Never |
| Guatemala | Usually | | | | | |
| Iraq | Usually | Usually | Usually | Usually | Usually | Occasionally |
| Jamaica | Usually | Usually | Usually | Usually | Usually | |
| Kazakhstan | Always | Occasionally | Always | Always | Always | Always |
| Libya | | Occasionally | Half the time | Usually | Half the time | Occasionally |
| Malaysia | Always | Always | Always | Usually | Usually | Always |
| Mexico | Usually | Occasionally | Occasionally | Half the time | Half the time | Occasionally |
| Moldova | | | | | | |
| Montenegro | Always | | Always | Always | Always | |
| Namibia | Usually | | | Usually | Always | |
| North Macedonia | Usually | Never | Half the time | Usually | Usually | Never |
| Peru | Always | Always | Always | Always | Usually | Usually |
| Romania | Always | Usually | Usually | Always | Always | Always |
| Russia | Always | Usually | Usually | Always | Always | Usually |
| Serbia | Always | Usually | Usually | Always | Always | Always |
| South Africa | Usually | Never | Usually | Usually | Half the time | Never |
| Suriname | Occasionally | | | | | |
| Thailand | Usually | Usually | Usually | Always | Always | Usually |
| Türkiye | Always | Always | Always | Always | Always | Always |
| Turkmenistan | Occasionally | Never | Never | Never | Never | Never |

| Always | |
|---------------|--|
| Usually | |
| Half the time | |
| Occasionally | |
| Never | |
| Not available | |

Low + Lower-middle income

Country

Algeria

Banglades Bolivia

Cambodia

Cameroon

Egypt El Salvado

Ghana Haiti

Honduras India

Indonesia

Iran

Kenya

Lebanon

Mongolia

Morocco Myanmar

Nicaragua

Nepal

Nigeria

Pakistan

Palestine

Papua Nev

Philippines Sri Lanka

Tunisia

Tanzania Uzbekistan

Vanuatu Vietnam

Zambia

Zimbabwe

Afghanista

Burkina Fa

Madagasca

Ethiopia

Liberia

Malawi

Rwanda

Somalia

Sudan

Syria

Uganda Yemen

Venezuela

Niger

| | BREAST | MELA | NOMA | | LUNG | |
|--------|---|----------------|---------------|---|----------------|-------------------------------|
| | Trastuzumab +BS | Nivo | Pembro | Erlotinit | Gefitinib | Afatani |
| | Always | | | Always | Always | |
| | Occasionally | Always | Half the time | Always | Always | Usually |
| | Usually | | | Occasionally | Occasionally | Occasional |
| | Always | Usually | Usually | Always | Always | Occasional |
| | Usually | Occasionally | Occasionally | | | |
| | Always | Usually | Usually | Half the time | Always | Occasional |
| | Half the time | | | Half the time | Occasionally | |
| | Always | | | | | |
| | Occasionally | Never | Never | Never | Never | Never |
| | Usually | | Usually | | | |
| | Always | Never | Never | Never | Never | Never |
| | Always | Always | Always | Always | Always | Always |
| | Always | Always | Always | Always | Always | |
| | Half the time | 25-50% cost | 25-50% cost | Usually | Half the time | |
| | Usually | | | | | |
| | Always | | | | | |
| | Always | | Always | Always | Always | Always |
| | | | | | | |
| | Usually | Half the time | Half the time | Usually | Usually | Usually |
| | Usually | Occasionally | Occasionally | Usually | Usually | |
| | Always | | | Usually | | |
| | Half the time | Always | Usually | Half the time | Half the time | Occasional |
| | Never | Never | Never | Never | Never | Never |
| Guinea | Occasionally | | | Occasionally | Occasionally | |
| | Always | | Always | Always | Always | Always |
| | Usually | | | | | |
| | Always | | | | Half the time | |
| | Never | Half the time | Half the time | | | |
| | Usually | Usually | Usually | Usually | Usually | Usually |
| | Usually | | | | | |
| | Usually | Never | Half the time | Usually | Usually | Usually |
| | | | | | | |
| | Half the time | | | Never | Half the time | |
| | Occasionally | | | | | Never |
| | | | | | | |
| 0 | | Never | Never | Occasionally | Occasionally | Occasional |
| 0 | Never | Never | Never | Occasionally | Occasionally | Occasional |
| 0 | Never | Never | Never | | | |
| | | | | Never | Never | Never |
| | Never Occasionally Never | Never Never | Never | | | |
| | Never Occasionally | | | Never | Never | Never |
| | Never Occasionally Never Occasionally | Never | Never | Never Never | Never | Never |
| | Never Occasionally Never Occasionally Always | | | Never | Never | Never |
| | Never Occasionally Never Occasionally Occasionally Always Never | Never | Never | Never Never | Never | Never |
| | Never Occasionally Never Occasionally Always | Never | Never | Never Never Occasionally | Never Never | Never |
| | Aever Occasionally Aever Occasionally Always Never Occasionally | Never | Never | Never Never Occasionally Half the time | Never | Never |
| 0 | Never Occasionally Never Occasionally Occasionally Always Never | Never | Never | Never Never Occasionally | Never Never | Occasionali Never Never |

RESULTS 2017



2017 ESMO INTERNATIONAL CONSORTIUM STUDY ON THE AVAILABILITY, OUT-OF-POCKET COSTS AND ACCESSIBILITY OF ANTINEOPLASTIC MEDICINES IN COUNTRIES OUTSIDE OF EUROPE

SPECIAL ARTICLE

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe

N. I. Cherny^{1*}, R. Sullivan², J. Torode³, M. Saar⁴ & A. Eniu^{5,6}


Annals of Oncology 28: 2633–2647, 2017



COST AND
AVAILABILITY OFMULTI-USEESSENTIALHiMEDICINES WHENPATIENT HAS A VALIDPRESCRIPTION


| Free | |
|-------------------------|--|
| <25% cost | |
| 25-50% cost | |
| Discount >50% and <100% | |
| Full cost | |
| Not available | |
| Missing data | |

MADRID 2023



ACCESSIBILITY OF MULTI-USE ESSENTIAL MEDICINES

| Always |
|---------------|
| Usually |
| Halfthe time |
| Occasionally |
| Never |
| Not available |
| Missing data |



MADRID 2023

LESSONS LEARNED?



ESSENTIAL MEDICINES AFFORDABILITY IN LOW AND LOW-MIDDLE INCOME COUNTRIES



"Old, inexpensive" cancer medicines

> Often only at full cost as an out-of-pocket expenditure (OOP)



New expensive biological (ESMO-MCBS 4-5 scores and A –B scores) > Usually only at full cost as an out-of-pocket expenditure (OOP)

Not much has changed in the past 5 years

ESSENTIAL MEDICINES <u>ACCESSIBILITY</u> IN LOW AND LOW-MIDDLE INCOME COUNTRIES



"Old, inexpensive" cancer medicines

> Often unreliable

> Non-continuous availability and unreliable procurement



Not much has changed in the past 5 years

LIMITATIONS OF THE STUDIES

Macro-level study, covering a wide range of medicines with a timeconstrained 'snapshot' of the situation

There <u>may be differences</u> within each country Accuracy of data

Accuracy of the data is dependent on the reporting accuracy of field reporters and their due diligence in verification of facts

The methodology incorporated **measures to minimise error**, including multiple reporters and cross-checks between reporters, and a process of open peer-review



ADDRESSING DISCREPANCIES



Realising the aspirations of the WHO EML list for cancer medicines requires new approaches



Ellen't Hoen (Director at Medicines Law and Policy) on '**Policy and intellectual property** regulatory instruments as tools to enhance access to expensive essential cancer medicines'



Kiusiang Tay-Teo (Technical Officer, World Health Organization) on 'Governmental policies to control cancer medicine prices'



ACKNOWLEDGEMENTS

MADRID ES

| Project Leader | 49 Collaborating | Partners | ESMO Officers | ESMO Staff | Reporters |
|----------------|--|--|---|---|--|
| ESMO | African Organisation for Research and Training in Cancer Albanian Oncology Association American Society of Clinical Oncology Armenian Association of Hematology and Oncology Argentine Association of Clinical Oncology Arsociation of Cancer Physicians Belgian Society of Medical Oncology Brazilian Society of Clinical Oncology Canadian Association of Medical Oncology Canadian Association of Medical Oncology Croatian Society of Medical Oncology Cyprus Oncology Society Czech Society for Oncology Danish Society of Medical Oncology Estonian Society of Medical Oncology Estonian Society of Oncology Pharmacy, coordinating with the International Society of Oncology Pharmacy Practitioners Finnish Society for Oncology German Society of Medical Oncology Hellenic Society of Medical Oncology Indian Society of Medical Oncology Indian Society of Medical Oncology Iranian Society of Medical Oncology Irsh Society of Medical Oncology Irsh Society of Medical Oncology Irsh Society of Medical Oncology Israeli Society of Medical Oncology Israeli Society of Clinical Oncology and Radiation Therapy | Italian Medical Oncology Association Japanese Society of Medical Oncology Korean Society for Medical Oncology Latvian Society for Medical Oncology Lithuanian Society of Oncology Luxembourg Society of Oncology Malaysian Oncological Society Medical Oncology Group of Australia Middle East Cancer Consortium Mexican Society of Oncology New Zealand Society for Oncology Norwegian Association of Oncology Philippine Society of Medical Oncology Polish Society of Medical Oncology Serbian Society of Medical Oncology Slovak Oncology Society Medical Oncology Society Serbian Society of Oncology Slovak Oncology Society Medical Oncology Society Medical Oncology Society Serbian Society of Oncology Slovak Oncology Society Medical Oncology Society of Oncology Swedish Society of Medical Oncology Swiss Society of Medical Oncology Swiss Society of Medical Oncology Taiwan Oncology Society Thai Society of Clinical Oncology Turkish Society of Medical Oncology | Nathan Cherny Elisabeth de Vries ESMO-MCBS WG: Dario Trapani Bishal Gyawali Felipe Roitberg ESMO Cancer Medicines Committee | Martina Galotti Nicola Latino Gracemarie Bricalli | All reporters who have completed the survey and the peer review |



THANK YOU

European Society for Medical Oncology (ESMO) Via Ginevra 4, CH-6900 Lugano T. +41 (0)91 973 19 00 esmo@esmo.org

esmo.org